Prelude Capital Management’s Travere Therapeutics TVTX Stock Holding History

Prelude Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,500	Closed	-$41K	–	2042
2018 Q2	$41K	Buy	+1,500	New	+$39.9K	﹤0.01%	1176
2018 Q1	–	Sell	-1,000	Closed	-$21K	–	1730
2017 Q4	$21K	Hold	1,000	–	–	﹤0.01%	1131
2017 Q3	$25K	Sell	1,000 -500	-33%	-$11K	﹤0.01%	1274
2017 Q2	$29K	Sell	1,500 -4,000	-73%	-$72.5K	﹤0.01%	1174
2017 Q1	$102K	Buy	+5,500	New	+$108K	0.01%	777
2016 Q4	–	Sell	-1,600	Closed	-$36K	–	1783
2016 Q3	$36K	Buy	+1,600	New	+$30.5K	﹤0.01%	1149
2015 Q4	–	Sell	-1,500	Closed	-$30K	–	1690
2015 Q3	$30K	Buy	+1,500	New	+$44.4K	﹤0.01%	1175
2015 Q2	–	Sell	-1,000	Closed	-$24K	–	2047
2015 Q1	$24K	Buy	+1,000	New	+$15.2K	﹤0.01%	1712

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Prelude Capital Management's TVTX Position: Q1 2026 in Review

Prelude Capital Management sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 20,599 shares — an estimated $787K sold.

Prelude Capital Management first reported a position in TVTX in Q2 2015 and held it in 19 quarters. The position peaked at $2.49M in Q3 2020. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

Prelude Capital Management reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
Prelude Capital Management sold 20,599 Travere Therapeutics shares in Q1 2026, an estimated $787K.
Prelude Capital Management first reported a position in Travere Therapeutics in Q2 2015 and held it in 19 quarters.
Prelude Capital Management's Travere Therapeutics position peaked at $2.49M in Q3 2020.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.